( June 26, 2024, 14:30 GMT | Official Statement) -- MLex Summary: French drugmaker Cooper Consumer Health has obtained conditional EU approval for its bid to buy the over-the-counter drug business of US rival Viatris. Approval is conditional on Cooper divesting the rights to its infant laxative medicine Bebegel in Portugal and, at the option of the purchaser, in France too. Additionally, Cooper must divest the rights to its earwax removal product Otowaxol in Germany and, at the option of the purchaser, in Ireland too.Statement follows....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.